AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV therapies Led by nontuberculous mycobacteria (NTM) expert Dr. Kevin Winthrop , trial will focus on early-stage, treatment-naive patients, a key difference from AN2’s previous studies in mycobacterium